纳塔利祖玛
多发性硬化
医学
复发-缓解
土耳其
物理疗法
肿瘤科
物理医学与康复
内科学
精神科
语言学
哲学
作者
M Tatar,T Özbalas,B Saraçoğlu,Ç Ölmez,B Yarci,AC Akdemir,C Yılmaz,S Şen
标识
DOI:10.1016/j.jval.2022.09.889
摘要
Multiple sclerosis is a neurodegenerative disorder with high economic and social burden due to its potential to cause severe disability. Around 85% of cases start as relapsing remitting MS (RRMS) but increasing number of patients gradually convert to secondary progressive MS (SPMS). The objective of this study is to evaluate the cost effectiveness of siponimod vs natalizumab for SPMS from the Turkish public payer’s (SGK) perspective.
科研通智能强力驱动
Strongly Powered by AbleSci AI